Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
Publication
, Journal Article
Gay, CL; James, KS; Tuyishime, M; Falcinelli, SD; Joseph, SB; Moeser, MJ; Allard, B; Kirchherr, JL; Clohosey, M; Raines, SLM; Montefiori, DC ...
Published in: J Infect Dis
March 2, 2022
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell-associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration. NCT03803605.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Infect Dis
DOI
EISSN
1537-6613
Publication Date
March 2, 2022
Volume
225
Issue
5
Start / End Page
856 / 861
Location
United States
Related Subject Headings
- Vorinostat
- Virus Latency
- Viremia
- Microbiology
- Humans
- HIV-1
- HIV Infections
- CD4-Positive T-Lymphocytes
- Broadly Neutralizing Antibodies
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Gay, C. L., James, K. S., Tuyishime, M., Falcinelli, S. D., Joseph, S. B., Moeser, M. J., … Margolis, D. M. (2022). Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. J Infect Dis, 225(5), 856–861. https://doi.org/10.1093/infdis/jiab487
Gay, Cynthia L., Katherine S. James, Marina Tuyishime, Shane D. Falcinelli, Sarah B. Joseph, Matthew J. Moeser, Brigitte Allard, et al. “Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” J Infect Dis 225, no. 5 (March 2, 2022): 856–61. https://doi.org/10.1093/infdis/jiab487.
Gay CL, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Moeser MJ, et al. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. J Infect Dis. 2022 Mar 2;225(5):856–61.
Gay, Cynthia L., et al. “Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” J Infect Dis, vol. 225, no. 5, Mar. 2022, pp. 856–61. Pubmed, doi:10.1093/infdis/jiab487.
Gay CL, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Moeser MJ, Allard B, Kirchherr JL, Clohosey M, Raines SLM, Montefiori DC, Shen X, Gorelick RJ, Gama L, McDermott AB, Koup RA, Mascola JR, Floris-Moore M, Kuruc JD, Ferrari G, Eron JJ, Archin NM, Margolis DM. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. J Infect Dis. 2022 Mar 2;225(5):856–861.
Published In
J Infect Dis
DOI
EISSN
1537-6613
Publication Date
March 2, 2022
Volume
225
Issue
5
Start / End Page
856 / 861
Location
United States
Related Subject Headings
- Vorinostat
- Virus Latency
- Viremia
- Microbiology
- Humans
- HIV-1
- HIV Infections
- CD4-Positive T-Lymphocytes
- Broadly Neutralizing Antibodies
- 42 Health sciences